Tiltan Pharma tiltanpharma.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Tiltan Pharma is a biotechnology company dedicated to the development and commercialization of its proprietary anti-angiogenic platform for the treatment of cancer and other indications. The Company is jointly owned by Yissum, the Technology Transfer Company of the Hebrew University, its entrepreneurs, Israeli investors and a group of Canadian investors.

Tiltan Pharma is a biotechnology company dedicated to the development and commercialization of its proprietary anti-angiogenic platform for the treatment of cancer and other indications. The Company is jointly owned by Yissum, the Technology Transfer...Show all

Company (Alive / Active)

Phone: +972-8-6473836

Fax:

1-1 Hi-tech Village
Edmond Safra Campus Givat Ram P.O.B.
Jerusalem, 91390
Israel

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Tiltan Pharma $3.5M Feb 5, 2014

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Tiltan Pharma Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Undisclosed InvestorsOtherUnattributed
Israel Innovation AuthorityGovernmentAirport City, IsraelBridge
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent Jul 04, 2007 Nov 23, 2010 Patent
Combination therapy for the treatment of cancer Jan 08, 2013 Application